The organoselenium compound 1,4-phenylenebis(methylene)selenocyanate inhibits 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorgenesis and enhances glutathione-related antioxidant levels in A/J mouse lung

Chemico-biological Interactions
John P RichieKaram El-Bayoumy

Abstract

Selenium, in the form of 1,4-phenylenebis(methylene)selenocyanate (p-XSC) but not Se-enriched yeast (Se-yeast), was highly effective at inhibiting lung tumors induced by the tobacco specific nitrosamine (TSNA) 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in A/J mice and at reducing NNK-induced DNA methylation and 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels in the lung. Our goal was to determine if p-XSC but not Se-yeast is effective at inducing levels of glutathione (GSH)-related antioxidants and reducing markers of GSH oxidation in the NNK-induced lung tumor model. In the first bioassay, 6-week-old mice were fed either control or experimental diets (containing 10 ppm as selenium from p-XSC or Se-yeast) and, beginning at 8 weeks of age, received NNK (3 micromol) by gavage once weekly for 8 weeks. After 18 weeks, p-XSC significantly reduced NNK-induced tumor burden by 74% (10.4 +/- 6.0 versus 2.7 +/- 1.5 tumors/mouse, P < 0.001) and tumor incidence from 96% to 68% (P < 0.01), whereas, Se-yeast had no effect. Lung GSH levels were unchanged by either NNK or Se-yeast, but were increased 70% in mice treated with both NNK and p-XSC (P < 0.01) and 41% in mice treated with p-XSC alone. In the second bioassay, the time course of...Continue Reading

References

Jun 1, 1985·Archives of Biochemistry and Biophysics·M E AndersonA Meister
Feb 1, 1984·Journal of Clinical Pathology·N I EllisB E Clayton
Jan 1, 1995·Free Radical Biology & Medicine·J F BilodeauA Castonguay
Jun 1, 1997·Environmental Health Perspectives·W A Pryor
Jun 24, 1998·Chemical Research in Toxicology·S S Hecht
May 16, 2000·Biochemical Pharmacology·W A Kleinman, J P Richie
Mar 10, 2001·Antioxidants & Redox Signaling·I Rahman
Apr 11, 2001·Mutation Research·K El-Bayoumy
Mar 12, 2003·Biochemical Pharmacology·Wayne A KleinmanJohn P Richie
Jun 24, 2003·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·H TapieroK D Tew
Aug 5, 2003·BioFactors·Regina Brigelius-Flohé, Leopold Flohé
Feb 21, 2004·Free Radical Biology & Medicine·Joshua E MuscatJohn P Richie
Jul 1, 2004·Mutation Research·Karam El-Bayoumy, Raghu Sinha
Jul 17, 2004·Journal of Cellular and Molecular Medicine·Daniela GiustariniIsabella Dalle-Donne
Aug 25, 2004·Nutrition·John P RichieJay A Zimmerman
Aug 16, 2005·Mutation Research·Karam El-Bayoumy, Raghu Sinha
Aug 18, 2005·Molecular Aspects of Medicine·Peter BrenneisenHelmut Sies

❮ Previous
Next ❯

Citations

Sep 28, 2010·Archives of Toxicology·Jela BrozmanováMiroslav Chovanec
Jul 2, 2011·Archives of Toxicology·Cristina W Nogueira, João B T Rocha
Jun 25, 2009·Nature Reviews. Cancer·Stephen S HechtDorothy K Hatsukami
Apr 5, 2011·Nutrition and Cancer·John P RichieKaram El-Bayoumy
Oct 29, 2009·Carcinogenesis·Christopher M LyonSteven A Belinsky
Jan 4, 2012·Experimental Gerontology·John P RichieKaram El-Bayoumy
May 18, 2007·Mutation Research·Renato Moreira RosaJoão Antonio Pêgas Henriques
Mar 25, 2010·BioFactors·Hwa Jin Jung, Young R Seo
May 12, 2011·Journal of Oncology·Hua-Chuan Zheng, Yasuo Takano
Jul 24, 2007·Current Opinion in Pharmacology·Wolfgang W Huber, Wolfram Parzefall
Jun 24, 2017·Analytical Chemistry·Wenyi ZhengMoustapha Hassan
Oct 23, 2010·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Daniel PlanoCarmen Sanmartín
Nov 1, 2018·Journal of Cellular Biochemistry·Sadra Samavarchi TehraniJafar Amani
Mar 22, 2008·Chemistry & Biodiversity·Regina Brigelius-Flohé
Oct 24, 2020·Oxidative Medicine and Cellular Longevity·Tiago E A FrizonJamal Rafique
Sep 15, 2017·Cancer Prevention Research·Steven A BelinskyDaniel D Karp
Sep 22, 2012·Chemical Research in Toxicology·Manicka V VadhanamRamesh C Gupta
Jul 7, 2009·Ecotoxicology and Environmental Safety·Maciej StepnikKonrad Rydzyński

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.